SAMSUNG E&A

Since entering the bio industry in 2011, We have expanded across the full spectrum of the sector — biopharmaceuticals, synthetic drugs and gene therapy. Through the consecutive delivery of facilities at the Songdo campus of Samsung Biologics, the world's largest biopharmaceutical contract manufacturing organization (CMO), we have helped build the largest single-site production infrastructure in the world.

Following the completion of Plant 4 in 2023, Plant 5 began operation in 2025 ahead of the original schedule, demonstrating our ability to compress delivery timelines in bio plant construction. In 2024 we completed a dedicated production facility for antibody-drug conjugates (ADC), a next-generation modality, further advancing our bio portfolio.

We have also accumulated technical capability through plants for leading Korean pharmaceutical companies including Dong-A Pharmaceutical, Hanmi Pharmaceutical and Reyon Pharmaceutical, and are widening our market by expanding our client base to new customers such as Sartorius and Chong Kun Dang, as well as through overseas projects. Built on process engineering and validation — the core capabilities of any bio plant — we deliver solutions optimized to each country, client and product, and will lead the global bio market.